Dr. Watts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1475 NW 12th Ave
Ste 3039
Miami, FL 33136Phone+1 305-243-1000Fax+1 305-243-8470- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
Emory University School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2009 - Present
FL State Medical License 2014 - 2026
NY State Medical License 2010 - 2014
Clinical Trials
- Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML Start of enrollment: 2020 Jun 18
Publications & Presentations
PubMed
- Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m) acute myeloid leukemia (AML).Brian A Jonas, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Jorge Cortes, Gary Schiller, Alice Mims, Gail J Roboz, Jus...> ;Leukemia & Lymphoma. 2024 Mar 27
- The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy.Venugopal, S., Watts, J.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
- E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.Jan Philipp Bewersdorf, Justin Taylor, Xiaoli Mi, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Sydney X Lu, Jessie Bourcier, Simon J Hogg, Ja...> ;Leukemia. 2023 Dec 1
- Join now to see all
Abstracts/Posters
- Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Justin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid LeukemiaJustin M. Watts, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Pevonedistat plus Azacitidine Shows Efficacy for Patients with Higher-Risk Myelodysplastic SyndromesSeptember 10th, 2021
DCC Volunteer Tiffany Davis Wishes She Could Be RidingFebruary 8th, 2018
Sylvester Researchers Conduct Promising Pilot Study of Precision Medicine for AMLDecember 14th, 2017- Join now to see all
Hospital Affiliations
University of Miami HospitalMiami, Florida
UMHC-Sylvester Comprehensive Cancer CenterMiami, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
